The Fort Worth Press - Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

USD -
AED 3.672504
AFN 63.503991
ALL 83.192586
AMD 375.730804
ANG 1.790083
AOA 917.000367
ARS 1385.503978
AUD 1.450747
AWG 1.8
AZN 1.70397
BAM 1.693993
BBD 2.007535
BDT 122.298731
BGN 1.709309
BHD 0.376597
BIF 2960.807241
BMD 1
BND 1.28353
BOB 6.91265
BRL 5.255304
BSD 0.996752
BTN 94.473171
BWP 13.741284
BYN 2.966957
BYR 19600
BZD 2.004591
CAD 1.38985
CDF 2282.50392
CHF 0.795017
CLF 0.023433
CLP 925.260396
CNY 6.91185
CNH 6.92017
COP 3662.985579
CRC 462.864319
CUC 1
CUP 26.5
CVE 95.504742
CZK 21.309304
DJF 177.489065
DKK 6.492704
DOP 59.330475
DZD 133.010264
EGP 52.642155
ERN 15
ETB 154.083756
EUR 0.866104
FJD 2.257404
FKP 0.752712
GBP 0.750441
GEL 2.680391
GGP 0.752712
GHS 10.921138
GIP 0.752712
GMD 73.503851
GNF 8739.335672
GTQ 7.62808
GYD 208.64406
HKD 7.82615
HNL 26.46399
HRK 6.545204
HTG 130.656966
HUF 338.020388
IDR 16990.8
ILS 3.13762
IMP 0.752712
INR 94.850204
IQD 1305.703521
IRR 1313250.000352
ISK 124.760386
JEP 0.752712
JMD 156.892296
JOD 0.70904
JPY 160.28704
KES 129.470356
KGS 87.450384
KHR 3992.031527
KMF 428.00035
KPW 900.00296
KRW 1508.00035
KWD 0.30791
KYD 0.830627
KZT 481.867394
LAK 21678.576069
LBP 89256.247023
LKR 313.975142
LRD 182.893768
LSL 17.115586
LTL 2.95274
LVL 0.60489
LYD 6.362652
MAD 9.315751
MDL 17.507254
MGA 4153.999394
MKD 53.388766
MMK 2098.832611
MNT 3571.142668
MOP 8.042181
MRU 39.797324
MUR 46.770378
MVR 15.450378
MWK 1728.292408
MXN 18.122104
MYR 3.924039
MZN 63.950377
NAD 17.115586
NGN 1383.460377
NIO 36.680958
NOK 9.70286
NPR 151.156728
NZD 1.745963
OMR 0.38408
PAB 0.996752
PEN 3.472089
PGK 4.307306
PHP 60.550375
PKR 278.184401
PLN 3.72275
PYG 6516.824737
QAR 3.634057
RON 4.427304
RSD 101.684639
RUB 81.295743
RWF 1455.545451
SAR 3.752751
SBD 8.042037
SCR 15.03876
SDG 601.000339
SEK 9.47367
SGD 1.292704
SHP 0.750259
SLE 24.550371
SLL 20969.510825
SOS 569.659175
SRD 37.601038
STD 20697.981008
STN 21.220389
SVC 8.721147
SYP 110.527654
SZL 17.114027
THB 32.495038
TJS 9.523624
TMT 3.5
TND 2.938634
TOP 2.40776
TRY 44.440368
TTD 6.772336
TWD 32.044404
TZS 2571.564679
UAH 43.689489
UGX 3713.134988
UYU 40.344723
UZS 12155.385215
VES 467.928355
VND 26337.5
VUV 119.385423
WST 2.775484
XAF 568.149495
XAG 0.014291
XAU 0.000222
XCD 2.70255
XCG 1.796371
XDR 0.706596
XOF 568.149495
XPF 103.295656
YER 238.603589
ZAR 17.12001
ZMK 9001.203584
ZMW 18.763154
ZWL 321.999592
  • RBGPF

    -13.5000

    69

    -19.57%

  • CMSD

    -0.0900

    22.66

    -0.4%

  • JRI

    -0.2700

    11.8

    -2.29%

  • BCC

    0.1400

    74.43

    +0.19%

  • AZN

    5.0200

    188.42

    +2.66%

  • GSK

    -0.1000

    53.84

    -0.19%

  • NGG

    -0.4800

    81.92

    -0.59%

  • BCE

    -0.2200

    25.25

    -0.87%

  • RIO

    0.8500

    86.64

    +0.98%

  • CMSC

    -0.0500

    22.77

    -0.22%

  • RELX

    -0.1000

    31.97

    -0.31%

  • VOD

    -0.1400

    14.49

    -0.97%

  • RYCEF

    -0.5900

    14.65

    -4.03%

  • BP

    0.5100

    46.68

    +1.09%

  • BTI

    0.3749

    57.8

    +0.65%

Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy
Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

TAMPA, FLORIDA / ACCESS Newswire / August 14, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the termination of its equity purchase agreement ("ELOC") with Hudson Global Ventures, LLC.

Text size:

The ELOC was an effective tool that nearly doubled the Company's original IPO raise. The decision to terminate the agreement reflects a strategic shift toward accretive financing and reinforces its aim of long-term shareholder value creation.

Management cited strong execution in expanding its independent pharmacy network, accelerating adoption of its AI-powered prescription routing technology and payment platforms, and creating a strong pipeline for growth opportunities with manufacturer direct-to-patient (DTP) platforms as drivers behind the move. This unique approach is designed to bypass traditional PBM barriers, increase manufacturer margins, and accelerate patient access.

"From a financial standpoint, terminating the ELOC aligns with our disciplined approach to capital structure and shareholder equity preservation," said Mark DiSiena, Chief Financial Officer of Wellgistics Health. "It allows us to secure more favorable funding opportunities so we can focus on our strategic plans, optimize our cost of capital, and pursue options that better reflect our growth trajectory."

"This decision reflects the discipline we're bringing to every part of the business," said Brian Norton, Chief Executive Officer of Wellgistics Health. "We've moved past the challenges of our opening quarters and are entering a new chapter built on operational strength and strategic execution. We're ready to show the market what we're truly capable of - delivering smarter, faster access to medicine, empowering independent pharmacies, and creating lasting value across the healthcare ecosystem."

About Wellgistics Health

Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ independent pharmacies and 200+ U.S. manufacturers, providing wholesale distribution, digital prescription routing, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health offers compliant, end-to-end solutions that restore access, transparency, and trust in U.S. healthcare.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, market conditions and other risks detailed in our reports and statements filed with the SEC. Investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Media Contact: [email protected]

Investor Relations: [email protected]

Investor Relations Contact:

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

G.Dominguez--TFWP